Metabolism open最新文献

{"title":"Eye care service utilization and associated factors among diabetic patients in Africa: A Systematic Review and Meta-Analysis","authors":"Worku Chekol Tassew ,&nbsp;Agerie Mengistie Zeleke ,&nbsp;Yeshiwas Ayal Ferede","doi":"10.1016/j.metop.2024.100293","DOIUrl":"https://doi.org/10.1016/j.metop.2024.100293","url":null,"abstract":"<div><h3>Introduction</h3><p>'Vision 2020, the Right to Sight', jointly coordinated by the World Health Organization's program for the prevention of blindness and deafness and the international agency for the prevention of blindness, was launched in 1999, however, the initiative faces many challenges to hitting its target. One of the challenges for this is, the absence of comprehensive data regarding eye care service utilization among diabetes mellitus patients in Africa. Therefore, this study was aimed at assessing the prevalence of eye care service utilization and associated factors among adult diabetes mellitus patients in Africa.</p></div><div><h3>Methods</h3><p>This systematic review and meta-analysis was conducted as per the international preferred reporting items for systematic review and meta-analysis protocols (PRISMA) guidelines. Published articles were searched using reputable databases (PubMed, Cochrane Library) and Web searches (Science Direct, African Journals Online, and Google Scholar). Quality appraisal was assessed based on the Joanna Briggs Institute's (JBI) critical appraisal checklist. The extracted data was exported to STATA version 11 (STATA Corp., LLC) for further analysis. Heterogeneity between the results of primary studies was assessed using Cochran's Q chi-square test and quantified with the I² statistics. Publication bias was assessed by visual inspection of the funnel plot and Egger's regression tests.</p></div><div><h3>Results</h3><p>The database search found 26,966 articles. The pooled prevalence of eye care service utilization among diabetic patients in Africa is found to be 40.92 % (95 % CI: 27.14–54.70, P &lt; 0.001). Good knowledge (POR = 3.57, 95 % CI: 2.67–4.76), good attitude (POR = 5.68, 95 % CI: 4.20–7.68), age greater than 65 years old (POR = 7.11, 95 % CI: 3.86–13.10), urban residence (POR = 5.03, 95 % CI: 2.12–11.96), and disease duration greater than 6 years (POR = 3.81, 95 % CI: 2.25–6.45) were factors associated with eye care service utilization.</p></div><div><h3>Conclusion</h3><p>This meta-analysis revealed that a high proportion of people with diabetes failed to use eye care services. Older age, good knowledge, urban residence and longer duration of illness were found to be the contributing factors for the utilization of eye care services in diabetes mellitus patients. Therefore, by considering the negative impact of low eye care service utilization, it is important to improve the habit of regular screening of the eye into routine assessment of diabetes mellitus follow up targeting patients with older age and longer duration of illness to reduce the magnitude of the problem.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100293"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000252/pdfft?md5=432519b1e9cad9ee3b2f44818a572f7d&pid=1-s2.0-S2589936824000252-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141291954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Manganese ions acts as a messenger to regulate serum lipid levels","authors":"Honglin Sun,&nbsp;Suzhen Chen,&nbsp;Junli Liu","doi":"10.1016/j.metop.2023.100268","DOIUrl":"10.1016/j.metop.2023.100268","url":null,"abstract":"","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100268"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936823000403/pdfft?md5=f6fe7919608452f7c3b19279f188cce9&pid=1-s2.0-S2589936823000403-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139014195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of finerenone on nephrotic syndrome in patients with diabetic kidney disease","authors":"Akira Mima,&nbsp;Yuta Saito,&nbsp;Keishi Matsumoto,&nbsp;Takahiro Nakamoto,&nbsp;Shinji Lee","doi":"10.1016/j.metop.2024.100294","DOIUrl":"https://doi.org/10.1016/j.metop.2024.100294","url":null,"abstract":"<div><h3>Introduction</h3><p>Diabetic kidney disease (DKD) is an important complication of diabetes as it results in end-stage renal disease; hence, several drugs have been developed for its treatment. However, even with treatment with renin-angiotensin system inhibitors and sodium-glucose cotransporter-2 inhibitors, the residual risk of DKD remains. While this risk is an issue, the renoprotective effects of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, are becoming evident. High proteinuria increases the risk of cardiovascular death as well as renal failure. Hence, it is especially important to address cases of urine protein to nephrotic levels in DKD, however, no previous studies have assessed the safety and efficacy of finerenone in patients with DKD and nephrotic syndrome. Therefore, this study aimed to assess whether finerenone has a renoprotective effect in advanced DKD complicated by nephrotic syndrome.</p></div><div><h3>Methods</h3><p>Nine patients with DKD and nephrotic syndrome who received 10–20 mg/day of finerenone were retrospectively analyzed. The average observation period was 9.7 ± 3.4 months. Patients with serum potassium levels greater than 5.0 mEq/L at the start of finelenone were excluded. Changes in urinary protein levels, estimated glomerular filtration rate (eGFR), and serum potassium levels were studied before and after finerenone administration.</p></div><div><h3>Results</h3><p>The mean changes in the urinary protein creatinine ratio (UPCR) at baseline were 6.6 ± 2.0. After finerenone treatment, the mean UPCR decreased to −0.6 ± 3.9; however, this change was not statistically significant.</p><p>The eGFR decline slope also tended to decrease with finerenone treatment (before vs. after: 3.1 ± 4.9 vs. −1.7 ± 3.2 mL/min/1.73 m². Furthermore, finerenone did not increase serum potassium levels.</p></div><div><h3>Conclusions</h3><p>Patients treated with finerenone showed decreased UPCR; hence, it is suggested that finerenone may be effective in treating nephrotic syndrome in patients with DKD. These findings may be applicable to real-world clinical settings. Nonetheless, it is important to note that this study was a retrospective analysis of a single-center cohort and had a limited sample size, highlighting the need for additional large-scale investigations.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100294"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000264/pdfft?md5=e8d9c8749c0c50fbc5b84e7d446096cc&pid=1-s2.0-S2589936824000264-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141286359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of adipose insulin resistance index with leg (gluteofemoral) fat (inverse) and serum alanine aminotransferase (positive) in young Japanese women","authors":"Satomi Minato-Inokawa ,&nbsp;Mari Honda ,&nbsp;Ayaka Tsuboi-Kaji ,&nbsp;Mika Takeuchi ,&nbsp;Kaori Kitaoka ,&nbsp;Miki Kurata ,&nbsp;Bin Wu ,&nbsp;Tsutomu Kazumi ,&nbsp;Keisuke Fukuo","doi":"10.1016/j.metop.2024.100289","DOIUrl":"10.1016/j.metop.2024.100289","url":null,"abstract":"<div><h3>Aim</h3><p>Associations of the adipose tissue insulin resistance index (AT-IR, a product of fasting insulin and free fatty acid) with body fat distribution and the ratio of alanine to aspartate aminotransferase (ALT/AST), a marker of hepatosteatosis, were examined in the context of the metabolic syndrome.</p></div><div><h3>Methods</h3><p>Legs, the trunk and body fat by DXA, blood pressure (BP) and blood chemistry were measured in 284 young Japanese female university students and 148 middle-aged biological mothers whose BMI averaged &lt;23 kg/m².</p></div><div><h3>Results</h3><p>Young women had higher leg fat/body fat and lower trunk fat/body fat ratio (both p &lt; 0.001) compared with middle-aged women but AT-IR did not differ between the two groups. We had multivariable linear regression analysis for AT-IR as a dependent variable including leg fat/body fat ratio, trunk fat/body fat ratio, fasting glucose, triglyceride, HDL cholesterol and systolic BP as independent variables. Leg fat/body fat ratio, fasting glucose and triglyceride (p = 0.013, 0.009 and 0.016, respectively) emerged as determinants of AT-IR in young women. Trunk fat/body fat ratio and fasting glucose (p = 0.003 and 0.019, respectively) emerged in middle-aged women. In a model which included ALT/AST as an additional independent variable, ALT/AST (p = 0.016) was the fourth independent determinant in young women and the single determinant of AT-IR in middle-aged women (p &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>In young Japanese women, adipose tissue insulin resistance was associated with reduced leg fat, a subtle partial lipodystrophy-like phenotype associated with reduced adipose tissue expandability. It was associated with elevated trunk (abdominal) fat in middle-aged women and with ALT/AST, a marker of hepatosteatosis, in two groups of Japanese women, suggesting ectopic fat deposition associated with reduced adipose tissue expandability.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100289"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000215/pdfft?md5=a53c5e9df5b28e499b32700efe92a632&pid=1-s2.0-S2589936824000215-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141231745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adipose-specific CLSTN3B gene associates with human obesity","authors":"Wenfei Li,&nbsp;Quanxin Jiang,&nbsp;Suzhen Chen,&nbsp;Junli Liu","doi":"10.1016/j.metop.2024.100269","DOIUrl":"10.1016/j.metop.2024.100269","url":null,"abstract":"","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100269"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S258993682400001X/pdfft?md5=51c3d9841c1862784c38fde36c0a30f7&pid=1-s2.0-S258993682400001X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139392148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal and spatial dynamics of immune response post myocardial infarction","authors":"Peihui Zhou,&nbsp;Suzhen Chen,&nbsp;Junli Liu","doi":"10.1016/j.metop.2024.100273","DOIUrl":"10.1016/j.metop.2024.100273","url":null,"abstract":"","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100273"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000057/pdfft?md5=d28abf2d53218db07191adc9862129be&pid=1-s2.0-S2589936824000057-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139882159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the potential of natural compounds in the fight against obesity","authors":"Ziwen Jia,&nbsp;Sijia Lu,&nbsp;Suzhen Chen,&nbsp;Junli Liu","doi":"10.1016/j.metop.2024.100271","DOIUrl":"10.1016/j.metop.2024.100271","url":null,"abstract":"","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100271"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000033/pdfft?md5=7ef5339e64f0d7a3686a524a20b3d926&pid=1-s2.0-S2589936824000033-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139457683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depletion of JunB increases adipocyte thermogenic capacity and ameliorates diet-induced insulin resistance","authors":"Qian Zhou,&nbsp;Suzhen Chen,&nbsp;Junli Liu","doi":"10.1016/j.metop.2024.100277","DOIUrl":"https://doi.org/10.1016/j.metop.2024.100277","url":null,"abstract":"<div><p>Adipose tissue is a crucial metabolic organ in the human body. It stores and exerts distinct physiological functions in different body regions. Fat not only serves as a cushion and insulator but also stores energy and conveys endocrine signals within the body. There is a growing recognition that adipose tissue is an organ that is misunderstood and underestimated in contribution to human health and disease progression by regulating its size and functionality. In mammals, the adipose tissue reservoir consists of three functionally distinct types of fat: white adipose tissue (WAT), brown adipose tissue (BAT), and beige or inducible brown adipose tissue (iWAT), which exhibits thermogenic capabilities intermediate between the other two. Fat in different depots exhibits considerable differences in origin, characteristics, and functions. They vary not only in adipocyte lineage, properties, thermogenesis, and endocrine functions but also in their immunological functions. In a recent study published in Nature Metabolism, Zhang et al. investigated the role of JunB in the thermogenic capacity of adipocytes and its significance in obesity and metabolic disorders. The study revealed that JunB expression in BAT coexists with both low and high thermogenic adipocytes, indicating a fundamental feature of heterogeneity and plasticity within BAT. In summary, this article demonstrates that research targeting JunB holds promise for improving diet-induced obesity and insulin resistance, offering new avenues for treating metabolic disorders.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100277"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000094/pdfft?md5=c5c93f8c314ced6d2f4f5cd84007b160&pid=1-s2.0-S2589936824000094-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antidiabetic activity of the aqueous extract of Erigeron floribundus leaves in streptozotocin-induced type 1 diabetes model in Wistar rats","authors":"Boutou Masky ,&nbsp;Hamadjida Adjia ,&nbsp;David Miaffo ,&nbsp;Bibi Farouck Aboubakar Oumarou ,&nbsp;Harquin Simplice Foyet ,&nbsp;Kakesse Maguirgue ,&nbsp;Ernest Rodrigue Talla ,&nbsp;Angele Kopodjing Bello ,&nbsp;Christian Bonabé ,&nbsp;Fidèle Ntchapda","doi":"10.1016/j.metop.2024.100288","DOIUrl":"https://doi.org/10.1016/j.metop.2024.100288","url":null,"abstract":"<div><h3>Backgroud</h3><p><em>Erigeron floribundus</em> is a herbaceous plant used in traditional Cameroonian medicine to treat diabetes mellitus. The aim of this study was to evaluate the antidiabetic properties of the aqueous extract of <em>E. floribundus</em> leaves (AEEF) in diabetic rats.</p></div><div><h3>Methods</h3><p>Diabetes was induced by a single intraperitoneal injection of streptozotocin (60 mg/kg) in normal rats fasted for 16 h. Subsequently, 30 diabetic male rats were divided into groups and treated orally for 21 days with distilled water (10 mL/kg), glibenclamide (3 mg/kg) and AEEF (300, 400, and 500 mg/kg). Body weight, food and water intake, blood glucose, insulin levels, lipid and oxidative profiles, as well as some markers of liver and kidney function were assessed. Histological sections of the rats' pancreas were taken.</p></div><div><h3>Results</h3><p>AEEF and glibenclamide significantly increased (p &lt; 0.001) body weight and decreased food and water intake in rats. A decrease in blood glucose (p &lt; 0.001) and an increase in insulin levels (p &lt; 0.001) were observed in the AEEF and glibenclamide groups. AEEF caused a significant (p &lt; 0.001) decrease in the levels of total cholesterol, LDL-c, triglycérides and coronary risk index (CRI), accompanied by a significant (p &lt; 0.001) increase in HDL levels and HOMA-β in rats. AEEF showed an improvement (p &lt; 0.001) in CAT and SOD activity and GSH levels accompanied by a significant decrease (p &lt; 0.001) in malondialdehyde levels. In addition, ALAT and ASAT activity, urea and creatinine levels were significantly reduced (p &lt; 0.001) after treatment with AEEF and glibenclamide. The extract also improved the size of Langerhans Islets in the pancreas of diabetic rats.</p></div><div><h3>Conclusion</h3><p>AEEF contains several bioactive compounds conferring antidiabetic, anti-dyslipidemic and antioxidant properties, thus justifying its therapeutic use in the treatment of diabetes mellitus.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100288"},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000203/pdfft?md5=22b5e81aeb49ac294a27975b00ff4ad9&pid=1-s2.0-S2589936824000203-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141163789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Once-weekly insulin icodec versus once-daily long-acting insulins for type 2 diabetes mellitus: Systematic review and meta-analysis","authors":"Sandro Augusto Goncalves Ribeiro ,&nbsp;Matheus Pedrotti Chavez ,&nbsp;Larissa Calixto Hespanhol ,&nbsp;Caroline Cristine Almeida Balieiro ,&nbsp;Eric Paqualotto ,&nbsp;Rodrigo Ribeiro e Silva ,&nbsp;Mateus Gauza ,&nbsp;João Roberto de Sa","doi":"10.1016/j.metop.2024.100285","DOIUrl":"10.1016/j.metop.2024.100285","url":null,"abstract":"<div><h3>Background</h3><p>Insulin icodec is a novel, long-acting, once-weekly basal insulin analog. Its comparative efficacy and safety with basal once-daily insulins in type 2 diabetes mellittus is uncertain.</p></div><div><h3>Objective</h3><p>Evaluate potential efficacy, benefits and risks associated with icodec compared to once-daily basal insulin analogs (degludec or glargine).</p></div><div><h3>Methods</h3><p>We systematically searched PubMed, Cochrane, and Embase for randomized controlled trials (RCTs) published until June 2023 comparing icodec versus long-acting insulin analogs (degludec and glargine) in type 2 diabetes mellitus (T2DM) with at least 12 weeks of follow-up. Binary endpoints were assessed with risk ratios (RRs) and continuous endpoints were compared using mean differences (MDs), with 95% confidence intervals (CIs). The protocol was registered in PROSPERO (CRD42023452468).</p></div><div><h3>Results</h3><p>A total of seven RCTs and 3286 patients with T2DM were included, of whom 1509 (60.6%) received icodec treatment. The follow-up period ranged from 16 to 78 weeks. Compared with once-daily basal insulin analogs, icodec led to a greater improvement in HbA1c (MD -0.15%; 95% CI -0.21, −0.10; p &lt; 0.0001; I² = 0%) and time in range (TIR) (MD 2.83%; 95%CI 0.94; 4.71; p = 0.003; I² = 22%). Body weight was increased with icodec treatment (MD 0.78 Kg; 95%CI 0.42, 1.15; p &lt; 0.01; I² = 86%). There was also a higher rate of injection site reactions (RR 1.89; 95%CI 1.12, 3.18; p = 0.016; I² = 0%) and nasopharyngitis (RR 1.94; 95%CI 1.11, 3.38; p = 0.020; I² = 0%) in the icodec group, compared with once-daily regimens. There was no significant difference between groups in fasting plasma glucose.</p></div><div><h3>Conclusions</h3><p>In this meta-analysis of RCTs, insulin icodec led to better control of HbA1c and TIR as compared with once-daily insulin regimens, albeit with increased weight gain and a higher rate of injection site reaction in the Icodec group.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"22 ","pages":"Article 100285"},"PeriodicalIF":0.0,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000173/pdfft?md5=73a126f4995fbfe901eb8c78fdbb4c27&pid=1-s2.0-S2589936824000173-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141137197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}